GlassScriptPhysician profile
Michael Wisher
NPI 1467454942
$15,483.27
in general payments reported to CMS, 2019-2025
20 companies · $4,123 in 2025
The $4,123 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,321 · 2022: $3,304 · 2023: $2,623 · 2024: $3,112 · 2025: $4,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,858.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,760.35 | 2021-2025 | |
| Alkermes, INC. | $2,594.49 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,821.63 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,744.26 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $1,171.50 | 2021-2022 | |
| Lundbeck LLC | $1,033.78 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $864.14 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $766.45 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $477.27 | 2023-2025 | Auvelity |
| Corium, LLC | $297.35 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $252.88 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $165.33 | 2022-2025 | Uzedy |
| Vanda Pharmaceuticals INC. | $147.21 | 2021-2025 | Fanapt |
| Merck Sharp & Dohme LLC | $102.12 | 2021-2022 | |
| Almatica Pharma LLC | $99.11 | 2024-2025 | Loreev Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.75 | 2022-2023 | Spravato |
| Idorsia Pharmaceuticals US INC | $43.26 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $40.37 | 2022 | |
| Supernus Pharmaceuticals, INC. | $30.05 | 2023 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.